阿斯特捷利康旗下 Evinova 與 Astellas 和 BMS 合作，運用其人工智慧平台加速臨床試驗。
這項合作預示著產業正朝向人工智慧驅動的臨床開發重大轉變。
阿斯特捷利康旗下的 Evinova 公司與 Astellas 和 Bristol Myers Squibb 合作，運用其人工智慧平台加速臨床試驗，並透過共享資料提供人工智慧驅動的洞察。
Evinova, AstraZeneca's health-tech business, announced strategic collaborations with Astellas and Bristol Myers Squibb to accelerate global clinical development using its AI-native platform. By sharing operational data, the partners will enable the platform to provide benchmarks and smarter recommendations. This aims to speed up clinical trials, reduce costs, and improve patient outcomes by moving from manual, fragmented processes to intelligent, AI-first workflows.
這項合作預示著產業正朝向人工智慧驅動的臨床開發重大轉變。透過匯集資料並運用人工智慧，阿斯特捷利康及其合作夥伴能大幅縮短藥物開發時程、降低失敗率，並在更快將新療法推向市場方面取得競爭優勢。
Where this signal fits in the broader landscape.
No recent signals tracked yet.
https://www.astrazeneca.com/media-centre/press-releases/2026/evinova-announces-strategic-collaborations-with-astellas-and-astrazeneca-to-scale-digital-health-solutions.html
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
登录